Cite

HARVARD Citation

    Bono, P. et al. (2020). Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. ESMO open. 5 (6), p. . [Online]. 
  
Back to record